Quantifying the World's Clinical Trial Efficacy, Tolerability, and Safety Information to Enable Good Drug Development Decisions

Dyslipidemia Database

The objective of the database is to extract all relevant changes in lipids, safety parameters, imaging outcomes and cardiovascular outcomes after treatment with statins, fibrates, cholesterol absorption inhibitors, niacin, or combinations thereof. The database is consisted of three types of studies. The first type includes trials that focus on short term (1 to 6 months) lipid modifying therapy and that report the lipid biomarker outcomes as their primary endpoint (biomarker trials). The second type includes trials that focus on cardiovascular event outcomes as their primary endpoint (event trials). The third type includes trials that focus on measures of progression of atherosclerosis as their primary endpoint (imaging trials).

Currently the Dyslipidemia - Lipid Outcomes Database is available for license. It contains information from 360 trials, representing trial-level data for over 137,000 patients. Key drugs include Atorvastatin, Rosuvastatin, Pravastatin, Lovastatin, Simvastatin, Cerivastatin, Fluvastatin, Pitavastatin, Fenofibrate, Fenofibric Acid (ABT335), Bezafibrate, Gemfibrozil, Ezetimibe, or Niacin (including Niaspan). The following biomarkers were extracted
• LDL: low-density lipoprotein cholesterol
• HDL: high-density lipoprotein cholesterol
• Triglycerides: total triglycerides
• Cholesterol: total Cholesterol
• non-HDL: non high-density lipoprotein cholesterol
• Apo-A1: apolipoprotein A-1
• Apo-B: apolipoprotein B
• CRP: C-reactive protein

The Dyslipidemia Database - Image Trial Outcomes and Dyslipidemia Database - CV Outcomes will be available in the coming months.